1. Home
  2. PSFE vs AUTL Comparison

PSFE vs AUTL Comparison

Compare PSFE & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paysafe Limited

PSFE

Paysafe Limited

HOLD

Current Price

$7.18

Market Cap

390.7M

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.41

Market Cap

431.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSFE
AUTL
Founded
1996
2014
Country
United Kingdom
United Kingdom
Employees
2900
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
390.7M
431.2M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
PSFE
AUTL
Price
$7.18
$1.41
Analyst Decision
Hold
Strong Buy
Analyst Count
4
4
Target Price
$8.69
$8.50
AVG Volume (30 Days)
397.0K
1.4M
Earning Date
03-03-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.33
EPS
N/A
N/A
Revenue
N/A
$10,120,000.00
Revenue This Year
$8.26
$669.62
Revenue Next Year
$6.30
$79.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
496.00
52 Week Low
$5.95
$1.11
52 Week High
$18.15
$2.70

Technical Indicators

Market Signals
Indicator
PSFE
AUTL
Relative Strength Index (RSI) 52.73 41.88
Support Level $6.61 $1.27
Resistance Level $7.39 $1.52
Average True Range (ATR) 0.35 0.08
MACD 0.00 -0.02
Stochastic Oscillator 39.47 14.29

Price Performance

Historical Comparison
PSFE
AUTL

About PSFE Paysafe Limited

Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Share on Social Networks: